Introduction
Mantle cell lymphoma (MCL) remains a clinical challenge due to its aggressive nature and the frequent development of resistance to standard therapies like the BTK inhibitor ibrutinib. While anti-CD20 antibodies such as rituximab are commonly used, their efficacy as monotherapy is often limited. This study evaluates MT-3724, a novel Engineered Toxin Body (ETB) designed to overcome these limitations by delivering a potent cytotoxic payload directly to CD20-positive cells.
Methods
MT-3724 is a fusion protein comprising a CD20-targeting single-chain variable fragment (scFv) and a modified Shiga-like toxin 1A (SLT-1A) subunit. Unlike standard antibody-drug conjugates, this ETB utilizes the toxin's natural ability to halt protein synthesis once internalized. The researchers tested MT-3724 across eight MCL cell lines, including the ibrutinib-resistant Jeko-R line. Efficacy was further validated in vivo using a patient-derived xenograft (PDX) mouse model derived from an ibrutinib-resistant patient. Signaling pathways were analyzed using Reverse Phase Protein Array (RPPA) to map the drug's impact on cellular signaling.
Results
Potency and Resistance Bypass
MT-3724 demonstrated significant growth inhibition across all tested MCL cell lines, with $IC_{50}$ values ranging from 78 to 1383 ng/mL. Crucially, the drug's efficacy was independent of ibrutinib sensitivity, as shown by its comparable activity in both sensitive and resistant lines (e.g., Jeko-1 vs. Jeko-R). This suggests that the mechanism of protein synthesis inhibition successfully bypasses common kinase-inhibitor resistance mutations.
Mechanism of Action and In Vivo Success
The drug induced dose-dependent apoptosis, evidenced by increased caspase 3/7 expression and PARP cleavage. Furthermore, MT-3724 treatment resulted in cell cycle arrest at the G0/G1 phase. In an ibrutinib-resistant PDX model, MT-3724 treatment led to a significant reduction in tumor volume and a marked increase in overall survival compared to vehicle-treated controls ($P < 0.01$). Interestingly, sensitivity did not strictly correlate with CD20 surface density, suggesting that internalization efficiency is a critical determinant of efficacy.
Synergistic Effects
MT-3724 exhibited strong synergy when combined with ibrutinib or the BCL-2 inhibitor ABT-199 (venetoclax). The ETB appears to lower the apoptotic threshold by reducing levels of anti-apoptotic proteins like MCL-1 and BCL-2, thereby sensitizing cells to secondary agents. This synergy was particularly evident in cell lines that were otherwise resistant to single-agent treatment.
Discussion
The findings highlight MT-3724's potential as a "molecular Trojan horse" capable of bypassing kinase-inhibitor resistance through a distinct mechanism of protein synthesis inhibition. While the Z-138 line showed relative insensitivity—possibly due to ILK and PAK signaling pathways—the overall results are highly promising. MT-3724 has entered Phase I/Ib clinical trials, which will be the ultimate test of its translational potential in patients with relapsed or refractory B-cell malignancies.
Summary updated